AR059301A1 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE

Info

Publication number
AR059301A1
AR059301A1 ARP070100451A AR059301A1 AR 059301 A1 AR059301 A1 AR 059301A1 AR P070100451 A ARP070100451 A AR P070100451A AR 059301 A1 AR059301 A1 AR 059301A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
dosage form
oral dosage
treatment
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR059301A1 publication Critical patent/AR059301A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente está dirigida a métodos y composiciones para la intervencion terapéutica de complicaciones vasculares asociadas con la diabetes, las hiperlipidemias, y varios trastornos cardiovasculares que incluyen, pero sin limitacion, hipertension recalcitrante, enfermedad arterial coronaria, hipertension arterial pulmonar, insuficiencia cardiaca congestiva, y anemias hemolíticas. En forma más específica, la memoria descriptiva describe métodos y composiciones para tratar estos trastornos vasculares utilizando composiciones que comprenden la BH4 y sus derivados. Se contemplan terapias de combinacion de la BH4 y otros regímenes terapéuticos. Reivindicacion 1: 1 Una forma de dosificacion oral que comprende 100 mg de (6R)- tetrahidrobiopterina (BH4) o un precursor o derivado de la misma. Reivindicacion 2: La forma de dosificacion oral de la reivindicacion 1 que comprende además un agente terapéutico.This is directed to methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders that include, but are not limited to, recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias More specifically, the specification describes methods and compositions for treating these vascular disorders using compositions comprising BH4 and its derivatives. Combination therapies of BH4 and other therapeutic regimens are contemplated. Claim 1: 1 An oral dosage form comprising 100 mg of (6R) -tetrahydrobiopterin (BH4) or a precursor or derivative thereof. Claim 2: The oral dosage form of claim 1 further comprising a therapeutic agent.

ARP070100451 2006-02-03 2007-02-02 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE AR059301A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76497906P 2006-02-03 2006-02-03
US81784706P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
AR059301A1 true AR059301A1 (en) 2008-03-26

Family

ID=39272765

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100451 AR059301A1 (en) 2006-02-03 2007-02-02 METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE

Country Status (3)

Country Link
AR (1) AR059301A1 (en)
PE (1) PE20071234A1 (en)
TW (1) TW200806296A (en)

Also Published As

Publication number Publication date
PE20071234A1 (en) 2008-01-14
TW200806296A (en) 2008-02-01

Similar Documents

Publication Publication Date Title
HK1258159A1 (en) Prolyl hydroxylase inhibitors and methods of use
BR112012010766A2 (en) compositions and methods of treating colitis and other intestinal diseases
BRPI0607003A2 (en) sustained release dosage form and method for sustained release of a substituted pyrazine compound
NO20090591L (en) Metabolism modulators as well as the treatment of related disorders
AR067326A1 (en) IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE
NO20074824L (en) Extension of time to disease progression or survival in cancer patients
JP2008545703A5 (en)
JP2007521835A5 (en)
EA200601648A1 (en) GLUCOSAMINE AND GENERAL PROCEDURES GLUCOSAMINE / ANTI-INFLAMMATORY AGENT, COMPOSITIONS AND METHODS
HRP20110969T1 (en) Pimobendan to be used for the reduction of heart size in mammals suffering from heart failure
ES2421556T3 (en) Use of cardiac hormones to diagnose the risk of cardiovascular complications as a result of cardiotoxic medications
SV2009002900A (en) DIARILURE FOR THE TREATMENT OF PULMONARY HYPERTENSION
WO2007023154A3 (en) Iron (iii) complex compounds for treating iron deficiency in patients with chronic inflammatory intestinal diseases
CL2008003201A1 (en) Pharmaceutical composition comprising 0.5 to 50 mg of gaboxadol or a pharmaceutically acceptable salt thereof, and one or more inhibitors of pat1 and / or one or more inhibitors of oat, wherein said composition provides an in vivo plasma profile with a tmax longer than 20 minutes, useful in sleep disorders treatments.
NO20076405L (en) Use of 24-nor-UDCA
EA200970127A1 (en) MODULATOR OF GLUCOCORTICOSTEROID RECEPTORS AND METHODS OF ITS APPLICATION
ATE480229T1 (en) ORAL PHARMACEUTICAL COMPOSITION FOR TREATING A COX-2-MEDIATED DISEASE
AR059301A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE
ES2578729T3 (en) Therapeutic agent for liver related diseases
EA201171229A1 (en) THERAPEUTIC APPLICATION OF HINAZOLINDION DERIVATIVES IN CARDIOVASCULAR DISEASES
JP2020506169A5 (en)
AR038632A1 (en) PHARMACEUTICAL COMPOSITION
EA201000739A1 (en) NEW MEDICAL APPLICATION OF SALTS 3- (2,2,2-TRIMETHYL HYDRAZINIUM) PROPIONATE
AR054126A1 (en) USE OF A BENZOILDERIVED FROM 3-AMINOCARBAZOL FOR THE PRODUCTION OF A PHARMACO FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH THE PRODUCTION OF PROSTAGLANDIN E2 (PGE2)
JP2008031164A5 (en)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal